FTC Extends Enforcement Date of Red Flags Rule
Client Alert | 1 min read | 08.03.09
The Federal Trade Commission (the "FTC") announced that it has postponed enforcement of the Red Flags Rule1 until November 1, 2009. This is the third enforcement extension by the FTC. The Red Flags Rule became effective January 1, 2008 and the mandatory enforcement date was originally November 1, 2008. The FTC suspended enforcement of the Rule until May 1, 2009 and subsequently suspended enforcement until August 1, 2009.2
The Red Flags Rule requires financial institutions and creditors to look for "red flags" that signal possible identity theft. The FTC announced that it has provided this additional extension since small businesses and entities with a low risk of identity theft remain uncertain of their obligations. The FTC intends to provide additional guidance to assist these companies. The FTC explained in a July 29th press release that these steps are consistent with the House Appropriations Committee's request that the FTC defer enforcement in conjunction with additional efforts to minimize the burden on health care providers and small businesses with a low risk of identity theft problems.
Please let us know if you have any questions or if we can help you in crafting a compliant Program.
1 72 Fed. Reg. 63717, 63771-63775 (Nov. 9, 2007) (codified at 16 C.F.R. Part 681).
2 The enforcement delay does not apply to the address discrepancy and credit card issuer rules. These rules are not addressed in this Health Law Alert.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
